INTI
Inhibitor Therapeutics, Inc.0.0470
-0.0010-2.08%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
8.11MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Inhibitor Therapeutics narrowed its Q3 operating loss to $741k from $813k a year ago, while nine-month net loss widened slightly to $2.0M from $1.9M amid steady R&D at $0.4M quarterly but lower G&A and interest income. Cash burned $2.6M YTD, leaving $3.0M at quarter-end September 30, 2025, with $3M deferred revenue intact. Expenses held firm as the firm advances its itraconazole formulation with Avior and awaits FDA pre-IND feedback on BCCNS. Cash runway covers the FDA push. Government shutdowns threaten regulatory timelines.
8-K
New consulting deal, equity plan
Inhibitor Therapeutics inked a performance-based services deal with Frameshift Management on October 21, 2025, for biostatistics, regulatory, and strategic consulting on its itraconazole program targeting basal cell carcinomas in Gorlin's syndrome, including HP2001 data re-analysis and FDA meeting prep. Compensation ties to milestones like FDA meeting requests, plus 18 million unvested 4-year warrants vesting on program sale, merger, or approval. Board approved 2025 Equity Incentive Plan with 20 million share reserve. Shareholder nod required within 12 months.
10-Q
Q2 FY2025 results
Inhibitor Therapeutics posted a Q2 net loss of $659,942, up from $501,690 y/y, driven by R&D expenses climbing to $325,623 from $239,776 on Avior engagement timing, while G&A edged to $370,150 from $345,371. Six-month net loss widened to $1.3M from $1.2M y/y, matching operating losses as interest income fell to $77,536 from $173,563. Cash burned $1.9M in operations (derived), dropping to $3.7M from $5.6M at year-start, with $3M deferred revenue steady. Cash lasts foreseeable future per management. FDA pre-IND advances for BCCNS itraconazole. Diluted EPS aligns at $(0.00) Q2, $(0.01) YTD. Stock comp adds no drag. No debt. Regulatory delays loom.
10-Q
Q1 FY2025 results
Inhibitor Therapeutics narrowed its Q1 2025 operating loss to $0.7M from $0.8M y/y, trimming R&D 9% to $0.2M and G&A 15% to $0.4M amid steady clinical prep. Net loss eased to $633K from $685K y/y, with interest income at $42K offsetting expenses; EPS holds at $(0.00) across 172M diluted shares. Cash dipped to $4.3M after $1.3M opex burn, yet management affirms runway for FDA itraconazole push without new trials. New office lease adds minor costs. Cash burn slowed. Regulatory approval remains uncertain.
10-K
FY2024 results
Inhibitor Therapeutics posted a FY2024 net loss of $3.3M on zero revenue, up from $3.0M in 2023, as R&D expenses climbed 22% y/y to $1.7M amid itraconazole formulation work with Avior Bio. Cash burned $3.2M but ended at $5.6M, enough for pre-IND push without new trials. Q4 saw steady burn while advancing novel itraconazole for BCCNS toward NDA. No dividends or buybacks. JHU license commits to modest annual royalties. Clinical delays could stall momentum.
HOTH
Hoth Therapeutics, Inc.
1.05-0.04
IKT
Inhibikase Therapeutics, Inc.
1.60-0.02
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
INDP
Indaptus Therapeutics, Inc.
2.21-0.10
INTS
Intensity Therapeutics, Inc.
0.44+0.02
ITRM
Iterum Therapeutics plc
0.40-0.02
LITS
Lite Strategy, Inc.
1.52-0.01
PHIO
Phio Pharmaceuticals Corp.
1.08-0.01
SMMT
Summit Therapeutics Inc.
17.23-0.15
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02